18-07-2018
miodrag ignjatovic / iStockphoto.com
US-based biopharmaceutical company AbbVie entered into a patent licensing agreement with generics company Mylan yesterday.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
AbbVie, Humira, Mylan, licence agreement, patent, patent agreement, Amgen, generics, biopharmaceuticals
Mylan fails to void MSD diabetes treatment patent at PTAB
11-05-2021
US Tax Court says Mylan can deduct patent litigation fees
29-04-2021
AbbVie and Momenta announce Humira patent licence agreement
08-11-2018
AbbVie enters Humira licensing deal with Fresenius Kabi
22-10-2018
AbbVie secures another Humira settlement
12-10-2018
AbbVie escalates Humira battle with Sandoz
13-08-2018
AbbVie and Alphabet company commit $1bn to collaboration
27-06-2018
AbbVie and Amgen settle Humira clash
29-09-2017
